about
The Potential of Trace Amines and Their Receptors for Treating Neurological and Psychiatric DiseasesThe functional role of monoamine oxidases A and B in the mammalian central nervous system.Schizophrenia, a neurodegenerative disorder with neurodevelopmental antecedents.Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators.Membrane permeability of trace amines: evidence for a regulated, activity-dependent, nonexocytotic, synaptic release.Apoptotic signaling cascades.A Permeability Study of O2 and the Trace Amine p-Tyramine through Model Phosphatidylcholine Bilayers.Glyceraldehyde-3-phosphate dehydrogenase as a target for small-molecule disease-modifying therapies in human neurodegenerative disorders.Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges.Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders.Aromatic L-amino acid decarboxylase: a neglected and misunderstood enzyme.Pharmacological characterization of a high-affinity p-tyramine transporter in rat brain synaptosomes.Apoptosis and human neurodegenerative diseases.Inhibition of monoamine oxidase-B by (-)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum.Prolongation of life in an experimental model of aging in Drosophila melanogaster.TAAR1 levels and sub-cellular distribution are cell line but not breast cancer subtype specificPhosphorylation and activation of brain aromatic L-amino acid decarboxylase by cyclic AMP-dependent protein kinaseThe effects of pargyline and 2-phenylethylamine on D1-like dopamine receptor bindingMolecular dynamics-based simulation of trace amine membrane permeabilityTrace Amines and Their ReceptorsTrace Amine-Associated Receptors as Novel Therapeutic Targets for Immunomodulatory DisordersIdentification of a subset of trace amine-associated receptors and ligands as potential modulators of insulin secretion
P50
Q22241322-91A30BB0-FE6A-42E9-88C2-67163AE983F8Q34060177-431C68EB-218B-47A8-A43F-C749E8D3F6F4Q34268457-B47B7FA7-A595-4D2D-AFB8-E26A835BDB27Q34330369-90EB9546-92D1-4F18-9C44-924EC2662C01Q34337752-D39CCE2E-49AD-44D0-8BBD-23AC63644C4AQ35092230-0D226782-7423-489A-AB1A-FFCFF24F2A4BQ35667396-B51ABE37-32CA-4F62-B6E8-8EA92AC1C6B9Q35919348-0E28A25A-4507-47BE-8793-7E135F5E9377Q39445109-4F7BA4AF-E98C-4850-AB92-596B4CDD6E49Q40576838-8758460A-CB89-4B1B-9DB0-1378846C28A3Q41193104-89E08FD8-F9E2-4D73-8BE0-E5C5723A1829Q41845623-A63C117B-5EBF-4E8E-9B7A-2AB178752F97Q48354835-4599F00A-D57F-4750-99A7-8D1402CB3ACEQ48667702-E173D0AF-1EB6-4F16-BF8E-90C8CE085E0BQ52568284-C43CA88E-7E7C-458B-A36D-747715452228Q64039259-BAA12D1B-833B-4C03-88FA-83952891926AQ74016089-84E71E89-892B-4AB6-B93E-8906B20534A7Q83061364-1E8B9AC9-E229-49B8-9006-4F07F3683288Q83140460-65637962-D261-41D9-998C-21F5495506AFQ89239795-C4ECFE51-1355-42A3-AF9F-A75C3C9D6FF7Q90258450-E31BA02F-8EAE-43AE-9C87-AFBD47AF99DCQ91070866-16488148-B3AD-4391-81D3-932A3441E4FC
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Mark D Berry
@ast
Mark D Berry
@en
Mark D Berry
@es
Mark D Berry
@nl
Mark D Berry
@sl
type
label
Mark D Berry
@ast
Mark D Berry
@en
Mark D Berry
@es
Mark D Berry
@nl
Mark D Berry
@sl
altLabel
Mark D. Berry
@en
prefLabel
Mark D Berry
@ast
Mark D Berry
@en
Mark D Berry
@es
Mark D Berry
@nl
Mark D Berry
@sl
P106
P1153
7402662286
P21
P31
P496
0000-0003-0172-0803
P569
2000-01-01T00:00:00Z